Preliminary trials with a combination of adriamycin (NSC-123127) and bleomycin (NSC-125066) in adult malignancies.
D000230:Adenocarcinoma / Q000188:drug therapy; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000328:Adult; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007958:Leukocyte Count; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D001761:Bleomycin; D004317:Doxorubicin